{"ATC Code":"QG02CB03","Abbreviation":[],"Aliases":["Dostinex","Cabaser","Cabergolina","Cabergolinum","FCE-21336","FCE 21336","Velactis","1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea","1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea","1-[(6-allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea","(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide","(8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide","Ergoline-8β-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-","1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea","(8R)-6-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)ergoline-8-carboxamide","1-((6-allylergoline-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea","1-[(6-allylergolin-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea","(8β)-N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-ergoline-8-carboxamide","1-(3-(dimethylamino)propyl)-3-ethyl-1-(((2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo(7.6.1.0^(2,7).0^(12,16))hexadeca-1(16),9,12,14-tetraen-4-yl)carbonyl)urea","1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-β-carbonyl)urea diphosphate","G02CB03","N04BC06","Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8β)-","1-(3-(dimethylamino)propyl)-3-ethyl-1-((2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo(7.6.1.02,7.012,16)hexadeca-1(16),9,12,14-tetraene-4-carbonyl)urea","Cabaseril"],"Biological Half-Life":"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.","CAS":"81409-90-7","ChEBI":"CHEBI:3286","ChEMBL":"CHEMBL1201087","ChemicalClasses":["lysergamide"],"Chirality":"achiral","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agonists","Drug Indication":"For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.","Erowid Experience Reports":[],"Esters":[],"European Community (EC) Number":"627-031-8","FDA Pharmacological Classification":"LL60K9J05T","Formating":[],"HMDB ID":"HMDB0014393","HeavyAtomCount":33,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agonists","IUPACName":"(6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide","InChI":"InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1","InChIKey":"KORNTPPJEAJQIU-KJXAQDMKSA-N","MeSH Pharmacological Classification":"Agents used in the treatment of Parkinson\u0026apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)","Melting Point":"102-104 °C","MolecularFormula":"C\u003csub\u003e26\u003c/sub\u003eH\u003csub\u003e37\u003c/sub\u003eN\u003csub\u003e5\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"451.6 g/mol","Pharmacodynamics":"Cabergoline stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D\u003csub\u003e1\u003c/sub\u003e and D\u003csub\u003e5\u003c/sub\u003e subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D\u003csub\u003e2\u003c/sub\u003e, D\u003csub\u003e3\u003c/sub\u003e and D\u003csub\u003e4\u003c/sub\u003e subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D\u003csub\u003e2\u003c/sub\u003e and D\u003csub\u003e3\u003c/sub\u003e receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D\u003csub\u003e2\u003c/sub\u003e- and D\u003csub\u003e3\u003c/sub\u003e-receptors. It also exhibits: agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)\u003csub\u003e2B\u003c/sub\u003e, 5-HT\u003csub\u003e2A\u003c/sub\u003e, 5-HT\u003csub\u003e1D\u003c/sub\u003e, dopamine D\u003csub\u003e4\u003c/sub\u003e, 5-HT\u003csub\u003e1A\u003c/sub\u003e, dopamine D\u003csub\u003e1\u003c/sub\u003e, 5-HT\u003csub\u003e1B\u003c/sub\u003e and 5-HT\u003csub\u003e2C\u003c/sub\u003e receptors and antagonist activity on \u0026alpha;\u003csub\u003e2B\u003c/sub\u003e, \u0026alpha;\u003csub\u003e2A\u003c/sub\u003e, and \u0026alpha;\u003csub\u003e2C\u003c/sub\u003e receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT\u003csub\u003e2A\u003c/sub\u003e agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion.","Physical Description":"Solid","PubChemId":54746,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Cabergoline","Name":"Cabergoline","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00248","Name":"Cabergoline","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/54746","Name":"Cabergoline","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201087","Name":"Cabergoline","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3286","Name":"Cabergoline","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=81409-90-7","Name":"Cabergoline","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014393","Name":"Cabergoline","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C08187","Name":"Cabergoline","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/LL60K9J05T","Name":"Cabergoline","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6022719","Name":"Cabergoline","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 54746, Cabergoline. Accessed July 27, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/54746\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/54746\u003c/a\u003e"],"SMILES":"CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C","SaltData":[],"Salts":[],"Solubility":"Insoluble","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 107.676 156\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h108v156H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M106.638 39.007 93.442 46.63M93.442 46.63l.003 11.39M90.293 63.692 80.25 69.494\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m81.469 68.789.003 12.023M79.03 68.79l.004 12.023\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M81.472 80.812 81.47 74.8M79.034 80.813l-.002-6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m80.25 69.494-10.047-5.797M67.048 58.027l-.003-11.39M67.045 46.637l13.196-7.623M80.241 39.014l-.004-15.24M80.237 23.774l10.043-5.802M93.432 12.3 93.429.91M96.587 17.97l10.047 5.797M63.896 63.699l-10.043 5.802\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.853 69.501-9.924-5.726M53.853 66.685l-8.705-5.022\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m43.929 63.775 4.962 2.863M45.148 61.663l4.353 2.511\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M53.507 84.741h.7l1.895-16.539-2.249 1.299-2.249-1.298z\" class=\"bond\"/\u003e\u003cpath d=\"m53.857 84.741-13.195 7.622\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M40.312 107.603h.7l1.899-16.943-2.249 1.299-1.97 1.138z\" class=\"bond\"/\u003e\u003cpath d=\"m40.662 107.603 13.208 7.62M53.87 115.223v15.24M53.87 130.463l-15.097 10.205\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m32.57 154.587 6.203-13.919M31.063 151.976l4.762-10.683\"/\u003e\u003c/g\u003e\u003cpath d=\"m32.57 154.587-11.822-1.246M16.603 149.171l-2.357-11.088\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 130.463 13.208 7.62M3.477 129.055l10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"M1.038 130.463v-15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 107.603-13.208 7.62M14.246 110.418l-10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.246 107.603 13.208 7.62M40.662 107.603l-13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M27.454 130.463v-15.24M25.016 129.055v-12.424\"/\u003e\u003c/g\u003e\u003cpath d=\"m38.773 140.668-11.319-10.205M14.246 138.083l13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.695 114.92.35.606\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m55.748 113.396.642 1.111M57.801 111.872l.934 1.616M59.853 110.348l1.227 2.122M61.906 108.824l1.519 2.627\"/\u003e\u003c/g\u003e\u003cpath d=\"m67.062 103.745-.005-11.389M53.857 84.741l13.2 7.615M70.217 109.413l10.049 5.795M80.266 115.208l.008 15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m80.274 130.448 13.202 7.613M82.711 129.039l11.983 6.91\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M95.387 64.32h-.721l-2.619-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.055h.03l-.018-.328-.024-.476q-.006-.262-.006-.482V59.42h.578zM99.693 64.32h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513V59.42h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M82.513 84.731q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.386 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524-.392.524-.392 1.453\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M68.99 64.327h-.72l-2.62-4.066h-.029l.029.595q.024.358.024.733v2.738h-.565v-4.899h.714l2.608 4.054h.029l-.018-.328-.023-.476q-.006-.262-.006-.482v-2.768h.577zM95.374 18.6h-.72l-2.62-4.066h-.029l.029.595q.024.357.024.732V18.6h-.565v-4.9h.714l2.608 4.055h.029l-.018-.328-.023-.476q-.006-.262-.006-.482V13.7h.577z\" class=\"atom\"/\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M43.521 60.826q0 .756-.255 1.327-.256.566-.757.881-.5.316-1.244.316-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.232.316.501.309.757.875.255.566.255 1.328m-3.863 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M19.356 155.44h-.721l-2.619-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.054h.03l-.018-.327-.024-.476q-.006-.262-.006-.482v-2.769h.578zM14.912 155.44h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M69.004 110.044h-.72l-2.62-4.065h-.029l.029.595q.024.357.024.732v2.738h-.565v-4.899h.714l2.607 4.054h.03l-.018-.327q-.012-.221-.023-.477-.006-.261-.006-.482v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m93.445 58.02-.001-5.695M90.293 63.692l-5.021 2.901M70.203 63.697l5.024 2.899M67.048 58.027l-.001-5.695M90.28 17.972l-5.022 2.901M93.432 12.3l-.002-5.695M96.587 17.97l5.024 2.898M63.896 63.699 58.874 66.6M20.748 153.341l5.911.623M20.748 153.341l5.911.623M16.603 149.171l-1.178-5.544M16.603 149.171l-1.178-5.544M67.062 103.745l-.003-5.695M70.217 109.413l5.025 2.897\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Cabergoline","UNII":"LL60K9J05T","Wikipedia":"Cabergoline","XLogP":3.4}